169 related articles for article (PubMed ID: 30288065)
1. Widespread amphotericin B-resistant strains of
Ashu EE; Korfanty GA; Samarasinghe H; Pum N; You M; Yamamura D; Xu J
Infect Drug Resist; 2018; 11():1549-1555. PubMed ID: 30288065
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
5. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
6. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
Barchiesi F; Spreghini E; Sanguinetti M; Giannini D; Manso E; Castelli P; Girmenia C
J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the MICs Obtained by Gradient Concentration Strip and EUCAST Methods for Four Azole Drugs and Amphotericin B against Azole-Susceptible and -Resistant
Dellière S; Verdurme L; Bigot J; Dannaoui E; Senghor Y; Botterel F; Fekkar A; Bougnoux ME; Hennequin C; Guitard J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844011
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.
Oakley KL; Moore CB; Denning DW
Antimicrob Agents Chemother; 1998 Oct; 42(10):2726-30. PubMed ID: 9756785
[TBL] [Abstract][Full Text] [Related]
9. Comparative Genome Sequence Analyses of Geographic Samples of
Fan Y; Wang Y; Xu J
Microorganisms; 2020 Oct; 8(11):. PubMed ID: 33126611
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
[TBL] [Abstract][Full Text] [Related]
12. Genetic Analyses of Amphotericin B Susceptibility in
Fan Y; Korfanty GA; Xu J
J Fungi (Basel); 2021 Oct; 7(10):. PubMed ID: 34682281
[No Abstract] [Full Text] [Related]
13. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.
Baddley JW; Marr KA; Andes DR; Walsh TJ; Kauffman CA; Kontoyiannis DP; Ito JI; Balajee SA; Pappas PG; Moser SA
J Clin Microbiol; 2009 Oct; 47(10):3271-5. PubMed ID: 19692558
[TBL] [Abstract][Full Text] [Related]
14. Discrepancies between MIC and MLC values of amphotericin B against isolates of Aspergillus species.
Colombo AL; McGough DA; Rinaldi MG
Mycopathologia; 1994 Dec; 128(3):129-33. PubMed ID: 7739726
[TBL] [Abstract][Full Text] [Related]
15. Surveillance for azoles resistance in Aspergillus spp. highlights a high number of amphotericin B-resistant isolates.
Reichert-Lima F; Lyra L; Pontes L; Moretti ML; Pham CD; Lockhart SR; Schreiber AZ
Mycoses; 2018 Jun; 61(6):360-365. PubMed ID: 29468746
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the semisolid agar antifungal susceptibility test with the NCCLS M38-P broth microdilution test for screening of filamentous fungi.
Kuzucu C; Rapino B; McDermott L; Hadley S
J Clin Microbiol; 2004 Mar; 42(3):1224-7. PubMed ID: 15004080
[TBL] [Abstract][Full Text] [Related]
17. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
18. Prior in vitro exposure to voriconazole confers resistance to amphotericin B in Aspergillus fumigatus biofilms.
Rajendran R; Mowat E; Jones B; Williams C; Ramage G
Int J Antimicrob Agents; 2015 Sep; 46(3):342-5. PubMed ID: 25979638
[TBL] [Abstract][Full Text] [Related]
19. Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan.
Moin S; Farooqi J; Jabeen K; Laiq S; Zafar A
Antimicrob Resist Infect Control; 2020 May; 9(1):62. PubMed ID: 32393344
[TBL] [Abstract][Full Text] [Related]
20. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
Manavathu EK; Abraham OC; Chandrasekar PH
Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
